Mediphage Bioceuticals
3:45 PM - 4:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
Mediphage, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene therapy platform based on its proprietary ministring DNA (msDNA) technology. A Toronto-based company, Mediphage uses a proprietary manufacturing process to develop safe and redosable gene therapies. msDNA is designed to overcome critical challenges facing viral gene therapies and leverage advancements in the non-viral delivery of nucleic acids.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2016
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
gene addition for Dravet Syndrome
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
